MAKO Surgical (NASDAQ: MAKO) was downgraded by investment analysts at Mizuho from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday. They currently have a $30.00 target price on the stock, down from their previous target price of $54.00.
Shares of MAKO Surgical traded down 0.65% during mid-day trading on Tuesday, hitting $26.10. MAKO Surgical has a 52 week low of $21.40 and a 52 week high of $45.15. The company’s market cap is $1.088 billion.
MAKO Surgical last issued its quarterly earnings data on Monday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.08. The company’s revenue for the quarter was up 50.7% on a year-over-year basis. On average, analysts predict that MAKO Surgical will post $-0.14 earnings per share next quarter.
MAKO has been the subject of a number of other recent research reports. Analysts at William Blair downgraded shares of MAKO Surgical from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday. Separately, analysts at Oppenheimer (NYSE: OPY) initiated coverage on shares of MAKO Surgical in a research note to investors on Thursday, April 12nd. They set a “market perform” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “hold” rating on shares of MAKO Surgical in a research note to investors on Wednesday, March 7th.
MAKO Surgical Corp. (MAKO) is a medical device company that markets its advanced robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures.